Skip to content

Search

Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us

Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us

Choose Speciality
Post content

Brain Cancer

Breast Cancer

HER2+ HRneg Breast Cancer

HR+ HER2neg Breast Cancer

TNBC

GI Cancers

Cholangiocarcinoma

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

GEJ

GIST

HCC

Pancreatic Cancer

GU Cancers

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

Gynecological Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Head & Neck Cancer

Nasopharyngeal Carcinoma

Oropharyngeal Cancer

Hematological Malignancies

Bone Marrow & Stem Cell Transplant

CAR-Ts

Leukemias

ALL

AML

Chronic Myeloid Leukemia

CLL/SLL

CMML

Lung Cancer

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lymphomas

DLBCL

Follicular Lymphoma

Hodgkin’s Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin’s Lymphoma

T-Cell Lymphoma

MPNs

Multiple Myeloma

Myelodysplastic Syndromes

Neuroendocrine Tumors

Sarcoma

Skin Cancer

Solid Tumors

Targeted Therapy

Thyroid Cancer

Uveal Melanoma

Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us

Drug Approvals
Regulatory News
Trial Results
Trial Status
Business News
Conference Coverage
About Us

Choose Speciality
Post content

Brain Cancer

Breast Cancer

HER2+ HRneg Breast Cancer

HR+ HER2neg Breast Cancer

TNBC

GI Cancers

Cholangiocarcinoma

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

GEJ

GIST

HCC

Pancreatic Cancer

GU Cancers

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

Gynecological Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Head & Neck Cancer

Nasopharyngeal Carcinoma

Oropharyngeal Cancer

Hematological Malignancies

Bone Marrow & Stem Cell Transplant

CAR-Ts

Leukemias

ALL

AML

Chronic Myeloid Leukemia

CLL/SLL

CMML

Lung Cancer

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lymphomas

DLBCL

Follicular Lymphoma

Hodgkin’s Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin’s Lymphoma

T-Cell Lymphoma

MPNs

Multiple Myeloma

Myelodysplastic Syndromes

Neuroendocrine Tumors

Sarcoma

Skin Cancer

Solid Tumors

Targeted Therapy

Thyroid Cancer

Uveal Melanoma

Search

Prostate Cancer Stat Facts & News

Ph 3 TALAPRO-2 study of TALZENNA® + XTANDI® in metastatic CRPC patients met primary endpoint of rPFS vs placebo plus XTANDI

October 12, 2022

Page1 … Page6 Page7 Page8

Onco-This-Week

Business News
Drug Approvals
Regulatory News
Trial Results
Trial Status
Conference Coverage

About Us

Sign up for OTW

Search

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.